Vancomycin
- Generic Name
- Vancomycin
- Brand Names
- Firvanq, Vancocin
- Drug Type
- Small Molecule
- Chemical Formula
- C66H75Cl2N9O24
- CAS Number
- 1404-90-6
- Unique Ingredient Identifier
- 6Q205EH1VU
- Background
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
...
- Indication
Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associ...
- Associated Conditions
- Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection
- Associated Therapies
- -
AbioKin - Antibiotic Kinetics
- Conditions
- Interventions
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2021-01-19
- Target Recruit Count
- 1500
- Registration Number
- NCT02609646
- Locations
- 🇮🇹
Ospedale S. Giovanni di Dio ASL 10, Servizio Anestesia e Rianimazione, Firenze, FI, Italy
🇮🇹Ospedale San Giovanni di Dio, Orbetello, Grosseto, Italy
🇮🇹Ospedale A. Manzoni, U.O. Anestesia e Rianimazione 1, Lecco, Lombardia, Italy
Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2
- Conditions
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Motif Bio
- Target Recruit Count
- 613
- Registration Number
- NCT02607618
- Locations
- 🇺🇸
St. Mary Medical Center ER, Long Beach, California, United States
🇺🇸California, Long Beach, California, United States
🇺🇸Georgia, Columbus, Georgia, United States
Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2015-11-16
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT02605213
- Locations
- 🇮🇷
Imam khomeini Hospital Complex, Tehran, Iran, Islamic Republic of
Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1
- Conditions
- Interventions
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- Motif Bio
- Target Recruit Count
- 600
- Registration Number
- NCT02600611
- Locations
- 🇺🇸
Nebraska, Lincoln, Nebraska, United States
🇺🇸Florida, Miami, Florida, United States
🇺🇸Washington, Seattle, Washington, United States
Intracameral Antibiotic Safety Study
- Conditions
- Interventions
- First Posted Date
- 2015-10-29
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Panhandle Eye Group, LLP
- Target Recruit Count
- 500
- Registration Number
- NCT02590523
- Locations
- 🇺🇸
Rush Eye, Amarillo, Texas, United States
Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA
- Conditions
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- Wayne State University
- Target Recruit Count
- 174
- Registration Number
- NCT02582203
- Locations
- 🇺🇸
St. John Hospital and Medical Center, Detroit, Michigan, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Detroit Medical Center, Detroit, Michigan, United States
Impact of Treatment With Colistin on Mortality Bacteremia Multiresistant Acinetobacter Baumannii Sensitive Colistin in Patients Critical
- Conditions
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2015-10-09
- Target Recruit Count
- 113
- Registration Number
- NCT02573064
FMT for Moderate to Severe CDI: A Randomised Study With Concurrent Stool Microbiota Assessment
- Conditions
- Interventions
- First Posted Date
- 2015-10-07
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 30
- Registration Number
- NCT02570477
- Locations
- 🇭🇰
Prince of Wales Hospital, Hong Kong, Hong Kong
Intestinal Lavage for the Treatment of Severe C. Difficile Infections
- Conditions
- Interventions
- First Posted Date
- 2015-06-09
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Lawson Health Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT02466698
- Locations
- 🇨🇦
London Health Sciences Centre, London, Ontario, Canada
A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis
- Conditions
- Interventions
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 8
- Registration Number
- NCT02464020
- Locations
- 🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.